Related Experiment Video
Updated: May 20, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
The molecular mechanism of the anticancer effect of atorvastatin: DNA microarray and bioinformatic analyses
Yan Gao1, Xue-Chun Lu, Hong-Ying Yang
1First Geriatric Cardiology Division, Chinese PLA General Hospital, Beijing 100853, PR China.
Abstract:
The aim of this study was to identify the molecular mechanisms and biological pathways associated with the anticancer effects of atorvastatin. For this purpose, we conducted cell-based microarray and bioinformatic analyses to determine the effect of atorvastatin exposure on endothelial cell response. The results of bioinformatic analysis performed using the Connectivity Map (cMap) to examine the atorvastatin-induced changes in gene expression in the human umbilical vein endothelial cell line, EA.hy926, indicated that treatment with 10 µM of atorvastatin for 24 h upregulated the expression of 295 genes and downregulated the expression of 354 genes by 2-fold compared to the control treatment. The gene set enrichment analysis (GSEA), the Database for Annotation, Visualization and Integrated Discovery (DAVID) pathway analysis, and Gene Ontology (GO) analysis of differentially expressed genes revealed that Kruppel-like factors (KLFs) and cell cycle-related genes were the genes most significantly affected by atorvastatin treatment. The upregulation of KLFs and the downregulation of the cell cycle-related genes, including cyclin (CCN)A2, CCNE2, CCNB1 and CCNB2, were validated by real-time polymerase chain reaction (RT-PCR). A comparison of the gene expression profile of atorvastatin-treated cells with that of the control cells and with that of 6,100 compounds in the cMap database revealed that the profile of atorvastatin-treated cells was highly similar to that of histone deacetylase (HDAC) inhibitor-treated cells. Therefore, these results suggest that atorvastatin acts as an HDAC, a G1/S (start) and a G2/M (mitosis) cell cycle inhibitor. These findings provide evidence of the feasibility of the use of atorvastatin as an anticancer drug.
Insights
Atorvastatin exhibits anticancer effects by inhibiting cell cycle progression and acting as a histone deacetylase (HDAC) inhibitor. This study reveals its potential as an anticancer drug by altering gene expression in endothelial cells.
Area of Science:
- Molecular Biology
- Bioinformatics
- Pharmacology
Background:
- Atorvastatin, a statin, is primarily known for its cholesterol-lowering effects.
- Emerging evidence suggests potential anticancer properties of statins.
- Understanding the molecular mechanisms underlying these effects is crucial for therapeutic development.
Purpose of the Study:
- To elucidate the molecular mechanisms and biological pathways responsible for atorvastatin's anticancer effects.
- To investigate the impact of atorvastatin on endothelial cell gene expression.
- To identify potential therapeutic targets and applications of atorvastatin in cancer treatment.
Main Methods:
- Cell-based microarray analysis of human umbilical vein endothelial cells (EA.hy926) treated with atorvastatin.
- Bioinformatic analyses including Connectivity Map (cMap), Gene Set Enrichment Analysis (GSEA), DAVID pathway analysis, and Gene Ontology (GO) analysis.
- Validation of differentially expressed genes using real-time polymerase chain reaction (RT-PCR).
Main Results:
- Atorvastatin treatment (10 µM, 24 h) significantly altered gene expression, upregulating 295 genes and downregulating 354 genes.
- Kruppel-like factors (KLFs) were upregulated, while cell cycle-related genes (e.g., CCNA2, CCNE2, CCNB1, CCNB2) were downregulated.
- Gene expression profiles of atorvastatin-treated cells closely resembled those of histone deacetylase (HDAC) inhibitor-treated cells.
Conclusions:
- Atorvastatin functions as a histone deacetylase (HDAC) inhibitor.
- It acts as a G1/S and G2/M cell cycle inhibitor, disrupting cell proliferation.
- These findings support the potential of atorvastatin as an anticancer therapeutic agent.
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Mechanisms of Retrovirus-induced Cancers
Mechanisms of Retrovirus-induced Cancers
DNA Microarrays

